PCSK9 and chronic kidney disease: Taken together, based on the lack of an effect of GFR on PCSK9 in CARE FOR HOMe and LURIC we would expect equal LDL-C lowering in CKD compared to non-CKD populations by pharmacologic inhibition of PCSK9.